Open Beta
TREN
MetriLume
TREN

US marketsALLO

SEC-sourced researchBeta

ALLO

Allogene Therapeutics, Inc.

Company comparison ↗

Data passport

CIK
0001737287
Exchange
Nasdaq
Business activity
Biological Products, (No Diagnostic Substances) · SIC 2836
Financial inputs
6/6
Filing date
Sep 30, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2024: 22,000.0000 USD; December 2025: 0.0000 USD22K USD0 USD0December 2024December 2025
ALLO · Exact amounts and source periods · USD
Period endRevenueFiling date
December 202422,000.0000Mar 12, 2026
December 20250.0000Mar 12, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 20250.0000-190,886,000.0000-149,246,000.0000415,905,000.0000123,363,000.0000Mar 12, 2026
December 202422,000.0000-257,590,000.0000-200,300,000.0000548,710,000.0000126,531,000.0000Mar 12, 2026

Explainable fundamental score

Five equally weighted components based on SEC financial inputs. No price inputs or personal investment preferences.

54/100
Profitability—
Growth0
Balance sheet70
Cash generation—
Data coverage100

Component weight: 20% · Minimum data coverage: 50% · Missing component value: 50/100

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenueFromContractWithCustomerExcludingAssessedTax$0Jan 1, 2025 – Dec 31, 2025Mar 12, 202610-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax$22KJan 1, 2024 – Dec 31, 2024Mar 12, 202610-K
Net incomeNetIncomeLoss-$190.89MJan 1, 2025 – Dec 31, 2025Mar 12, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$149.25MJan 1, 2025 – Dec 31, 2025Mar 12, 202610-K
Total assetsAssets$415.91MDec 31, 2025Mar 12, 202610-K
Total liabilitiesLiabilities$123.36MDec 31, 2025Mar 12, 202610-K

New filings

Explore methodology ↗